Author:
Bardakhivska K.I., ,Sarnatskaya V.V.,Gerashchenko B.I.,Nikolaev V.G., , ,
Abstract
Summary. Development of malignant neoplasms is a serious pathological condition accompained by a significant body intoxication. Complex application of surgery, radiation and chemotherapy greatly improves the results of treatment of the patients with cancer, however, their toxic effects are enhanced that manifested as suppression of hematopoesis, immunosupression, nephrotoxicity, hepatotoxicity, cardiotoxicity. Enterosorption using highly active carbon sorbents is one of the perspective methods of overcoming endotoxicosis caused by systemic intoxication. The results of the study obtained on laboratory animals, namely on mice with Leweis lung carcinoma, rats with Geren’s carcinoma treated with cisplatin, rats treated with melphalan, doxorubicin, as well as irradiated rats, showed excellent efficiency of carbon enterosorbents in reducing the toxic manifestations of radiation and chemotherapy. The enterosorbents showed a myeloprotective action, lead to significant improvement of some haematological and biochemical parameters of blood and reduced manifestations of oxidative stress and the level of endogenous intoxication.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference27 articles.
1. Kavetsky RE. Interaction between tumor and host. Kiev: Naukova dumka, 1977, 235 p. (in Russian).
2. Chekhun VF. The concept "tumor and host" in the post-genomic era. Exp Oncol 2010; 32 (3): 120-4.
3. Osinsky SP, Kelleher DK, Chekhun VF. "Tumor and host" by R.E. Kavetsky (1962): implication for the past, present and future. Exp Oncol 2012; 34 (2): 70-4.
4. Nikolaev VG, Sarnatskaya VV, Sakhno LA, et al. Sorption therapy as a modificator of tumor-host interaction. Ways and prospects for the development of experimental oncology in Ukraine 2021: 281-91.
5. Tas F, Eralp Y, Basaran M, et al. Anaemia in oncology ptactice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25 (4): 371-9. doi: 10.1097/00000421-200208000-00011.